Novavax Shares Gain After Filing With Serum Institute For WHO Emergency Use Listing For COVID-19 Vaccine

Novavax Inc NVAX and its partner Serum Institute of India Pvt. Ltd. (SII) have announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of its recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.
The submission is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI).
The grant of EUL by the WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility established to allocate and distribute vaccines equitably.
In addition to the submission for WHO EUL, SII and Novavax completed the submission of modules last month as required by regulatory agencies in India, Indonesia, and the Philippines.
Preliminary data reported last month showed that a single booster dose at six months of NVX-CoV2373 elicited a 4.6-fold increase in functional antibody titers.
A six-fold increase in cross-reactive functional antibodies to Delta variant compared to primary vaccination series was seen.
Price Action: NVAX stock is up 9.48% at $254 during the market session on the last check Thursday.
Image by hakan german from Pixabay